思创医惠(300078) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥314,655,998.45, representing a 1.67% increase year-over-year, while the year-to-date revenue decreased by 6.17% to ¥964,574,632.37[3]. - Net profit attributable to shareholders for Q3 2021 was ¥28,440,267.88, a decrease of 7.02% compared to the same period last year, and a year-to-date decrease of 27.47% to ¥55,850,321.75[3]. - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥20,662,036.14, a significant increase of 1,606.06% year-over-year, with a year-to-date increase of 1.17% to ¥28,855,296.45[3]. - Total operating revenue for the current period is ¥964,574,632.37, a decrease of 6.2% from ¥1,027,992,675.14 in the previous period[25]. - Net profit for the current period is ¥53,961,510.94, down 31.9% from ¥79,305,135.46 in the previous period[27]. - Basic and diluted earnings per share decreased to ¥0.0654 from ¥0.0886, a decline of 26.5%[28]. Assets and Liabilities - The company's total assets increased by 13.98% year-over-year, reaching ¥5,382,536,397.81 at the end of the reporting period[3]. - The company's total liabilities increased, with long-term borrowings rising by 47.26% to ¥852,500,635.59, reflecting a shift in financing structure[8]. - The company's total liabilities increased to CNY 2,407,107,163.49 from CNY 1,723,676,546.16, reflecting a growth of approximately 39.6%[23]. - The total current liabilities decreased to CNY 920,640,042.84 from CNY 1,129,899,965.62, a reduction of about 18.6%[23]. - The company's long-term borrowings rose to CNY 852,500,635.59 from CNY 578,917,980.54, indicating an increase of approximately 47%[23]. Cash Flow - Cash flow from operating activities for the year-to-date period was ¥20,263,579.85, reflecting a substantial increase of 164.18% compared to the previous year[9]. - Cash flow from operating activities generated a net amount of ¥20,263,579.85, compared to a net outflow of ¥31,574,966.66 in the previous period[31]. - Financing activities generated a net cash inflow of ¥687,042,340.02, compared to a net inflow of ¥82,548,100.36 in the previous period, indicating improved financing conditions[31]. - Investment activities resulted in a net cash outflow of ¥248,593,548.86, worsening from a net outflow of ¥166,318,115.96 in the previous period[31]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 49,954[11]. - The largest shareholder, Hangzhou Sichuang Medical Technology Group Co., Ltd., holds 10.50% of shares, totaling 90,912,612 shares[11]. - The second-largest shareholder, Lu Nan, owns 7.24% of shares, amounting to 62,739,500 shares[11]. - The company has a total of 33,493,668 shares repurchased, representing 3.87% of the total share capital[12]. - The company has a total of 90,912,612 unrestricted shares held by its largest shareholder[12]. Dividends and Share Capital - The company plans to distribute a cash dividend of 0.13 RMB per share based on the total share capital[16]. - As of September 30, 2021, the company's registered capital is 866,129,866 RMB[16]. - The convertible bond conversion price was adjusted from 8.27 RMB to 8.26 RMB per share[16]. - The company completed the cancellation of 3,281,600 restricted shares as part of its stock incentive plan[17]. - The total number of restricted shares at the end of the period is 29,811,359[15]. Other Financial Metrics - The company experienced a 58.95% decrease in other income to ¥26,908,513.56, mainly due to a reduction in government subsidies[9]. - The company reported an increase in financial expenses to ¥50,278,972.38 from ¥21,248,780.18, primarily due to higher interest expenses[25]. - The company implemented the revised Accounting Standard No. 21 for Leases starting January 1, 2021, resulting in adjustments to the financial statements[36].